cardiovascular
To sponsor this category, click here | subscribe to this category

Avandia: Off the Market or Not?

The Senate report that leaked on Avandia (rosiglitazone) over the weekend has made plenty of headlines . It quotes an internal FDA report that recommends flatly that the drug be removed from the market, since its beneficial effects can be achieved by use of the competing PPAR drug Actos (pioglitazone), which doesn’t seem to have the same cardiovascular risks. The two drugs have been compared (retrospectively) head to head, and Avandia definitely seems to have come out as inferior due to safety concerns.

Novartis snares Corthera heart drug in $620M buyout

In another sign that 2009 will end with a frenzy of new drug deals, Novartis is putting up $120 million to buy San Mateo, CA-based Corthera, securing complete control of the promising heart drug Relaxin and committing up to $500 million in milestones for the cardiovascular drug’s ultimate success. The $620 million deal underscores Novartis’ keen interest in expanding its work in cardiovascular disease. With its high blood pressure med Diovan facing the first wave of generic competition next year–and the erosion of sales for the $6 billion franchise–Novartis needs new drugs like Relaxin, which is in late-stage trials.

Tracleer – Stand

In Pulmonary arterial hypertension (PAH) WHO Class III or IV Tracleer stands alone Bosentan (BOZENTAN) is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (PAH). It is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of PAH under the trade name Tracleer. More on Wikipedia Brand name: Tracleer Generic name/category: Bosentan, Endothelin receptor antagonists Company: Actelion Country/Market: USA, North America Indication(s)/use: Pulmonary arterial hypertension (PAH) Target: Healthcare Professionals (HCP) Tagline: A cornerstone of oral therapy Medium: Print ad Size/duration: single-page Publication/Aired: Chest – September 2009 To see all of this brand's ads on AdPharm, click here 1 views Sep 19, 2009 Visit AdPharm.net for more pharmaceutical ads

Tracleer – Goes beyond

In Pulmonary arterial hypertension (PAH) WHO Class III or IV Tracleer goes beyond symptomatic relief Bosentan (BOZENTAN) is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (PAH). It is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of PAH under the trade name Tracleer. More on Wikipedia Brand name: Tracleer Generic name/category: Bosentan, Endothelin receptor antagonists Company: Actelion Country/Market: USA, North America Indication(s)/use: Pulmonary arterial hypertension (PAH) Target: Healthcare Professionals (HCP) Tagline: A cornerstone of oral therapy Medium: Print ad Size/duration: single-page Publication/Aired: Chest – August 2009 To see all of this brand's ads on AdPharm, click here 2 views Sep 19, 2009 Visit AdPharm.net for more pharmaceutical ads

Tracleer – Stand

In Pulmonary arterial hypertension (PAH) WHO Class III or IV Tracleer stands alone Bosentan (BOZENTAN) is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (PAH). It is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of PAH under the trade name Tracleer. More on Wikipedia Brand name: Tracleer Generic name/category: Bosentan, Endothelin receptor antagonists Company: Actelion Country/Market: USA, North America Indication(s)/use: Pulmonary arterial hypertension (PAH) Target: Healthcare Professionals (HCP) Tagline: A cornerstone of oral therapy Medium: Print ad Size/duration: single-page Publication/Aired: Chest – September 2009 To see all of this brand's ads on AdPharm, click here 1 views Sep 19, 2009

Crestor – little secret

“My diabetes and high cholesterol share an ugly little secret.” Diabetes and high cholesterol increase the risk of plaque buildup in arteries. That's why it's so important to manage your cholesterol. Rosuvastatin is a member of the drug class of statins, used to treat high cholesterol and related conditions, and to prevent cardiovascular disease.

Generic Metoprolol Succinate

FDA approves diabetes drug Onglyza

On Friday afternoon the FDA finally gave the green light to Type 2 diabetes drug Onglyza (saxagliptin), marking AstraZeneca’s first new drug approval in six year.

British Heart Foundation TV commercial

Heart attack symptoms awareness campaign British TV event about Heart attack from the British Heart Foundation A man is attached on a chair while another one proceeds to make him feel the symptoms of a heart attack by beating him. [supers] No two heart attacks are the same. Symptoms can be mild or severe

Aspirin 81

If you don’t tell your at-risk patients about the benefits of Aspirin 81 mg, who will? Order your samples now! Ensure that Aspirin 81 mg is a routine part of your patient conversation. Brand name: Aspirin 81 Generic name/category: acetylsalicylic acid, Non-steroidal anti-inflammatory drugs (NSAID), cardiovascular Company: Bayer Healthcare Country/Market: Canada, North America Target: Healthcare Professionals (HCP) Tagline: Your partner in prevention Publication: Doctor’s Review June 2009 To see all of the ads from this campaign, click here To see all of this brand’s ads on AdPharm, click here